| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Internal Medicine F (T.V., T.K.), Gentofte Hospital; Medical Physiology (T.V., J.J.H.), The Panum Institute; Clinical Pharmacology (J.S.), Gentofte Hospital; Endocrinology (S.M.), Hvidovre Hospital, DK-2650 Copenhagen; Biostatistics (A.V.), Novo Nordisk A/S; and Assay and Cell Technology (A.G.J.), Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Address all correspondence and requests for reprints to: Tina Vilsbøll, M.D., Department of Internal Medicine F, Gentofte Hospital, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark. E-mail: tivi{at}gentoftehosp.kbhamt.dk.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones secreted in response to meal ingestion, thereby enhancing postprandial insulin secretion. Therefore, an attenuated incretin response could contribute to the impaired insulin responses in patients with diabetes mellitus. The aim of the present investigation was to investigate incretin secretion, in obesity and type 1 and type 2 diabetes mellitus, and its dependence on the magnitude of the meal stimulus. Plasma concentrations of incretin hormones (total, reflecting secretion and intact, reflecting potential action) were measured during two meal tests (260 kcal and 520 kcal) in eight type 1 diabetic patients, eight lean healthy subjects, eight obese type 2 diabetic patients, and eight obese healthy subjects. Both in diabetic patients and in healthy subjects, significant increases in GLP-1 and GIP concentrations were seen after ingestion of both meals. The incretin responses were significantly higher in all groups after the large meal, compared with the small meal, with correspondingly higher C-peptide responses. Both type 1 and type 2 diabetic patients had normal GIP responses, compared with healthy subjects, whereas decreased GLP-1 responses were seen in type 2 diabetic patients, compared with matched obese healthy subjects. Incremental GLP-1 responses were normal in type 1 diabetic patients. Increased fasting concentrations of GIP and an early enhanced postprandial GIP response were seen in obese, compared with lean healthy subjects, whereas GLP-1 responses were the same in the two groups. ß-cell sensitivity to glucose, evaluated as the slope of insulin secretion rates vs. plasma glucose concentration, tended to increase in both type 2 diabetic patients (29%, P = 0.19) and obese healthy subjects (22% P = 0.04) during the large meal, compared with the small meal, perhaps reflecting the increased incretin response. We conclude: 1) that a decreased GLP-1 secretion may contribute to impaired insulin secretion in type 2 diabetes mellitus, whereas GIP and GLP-1 secretion is normal in type 1 diabetic patients; and 2) that it is possible to modulate the ß-cell sensitivity to glucose in obese healthy subjects, and possibly also in type 2 diabetic patients, by giving them a large meal, compared with a small meal.
This work was supported by the Danish Diabetes Association and the Novo Nordisk A/S Foundation.
Abbreviations: AUC, Area under the curve; BMI, body mass index; GIP, glucose-dependent insulinotropic polypeptide; GLP, glucagon-like peptide; ISR, insulin secretion rate.
This article has been cited by other articles:
 |
|
 |
|
  S. M. Yoder, Q. Yang, T. L. Kindel, and P. Tso Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G299 - G305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cornu, J.-Y. Yang, E. Jaccard, C. Poussin, C. Widmann, and B. Thorens Glucagon-Like Peptide-1 Protects {beta}-Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop Diabetes, August 1, 2009; 58(8): 1816 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Y. Enc, T. Ones, H. L. Akin, F. Dede, H. T. Turoglu, G. Ulfer, N. Bekiroglu, G. Haklar, J. F. Rehfeld, J. J. Holst, et al. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects Am J Physiol Gastrointest Liver Physiol, March 1, 2009; 296(3): G482 - G489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Lim, G. J. Huang, N. Flora, D. LeRoith, C. J. Rhodes, and P. L. Brubaker Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell Endocrinology, February 1, 2009; 150(2): 580 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Padidela, M. Patterson, N. Sharief, M. Ghatei, and K. Hussain Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period Eur. J. Endocrinol., January 1, 2009; 160(1): 53 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Greenfield, I S. Farooqi, J. M Keogh, E. Henning, A. M Habib, A. Blackwood, F. Reimann, J. J Holst, and F. M Gribble Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects Am. J. Clinical Nutrition, January 1, 2009; 89(1): 106 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J Larsen Mechanisms behind GLP-1 induced weight loss The British Journal of Diabetes & Vascular Disease, November 1, 2008; 8(2_suppl): S34 - S41. [Abstract] [PDF]
|
|
|
|
 |
|
 C. W. Chia and J. M. Egan Incretin-Based Therapies in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3703 - 3716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salehi, B. A. Aulinger, and D. A. D'Alessio Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins Endocr. Rev., May 1, 2008; 29(3): 367 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Lu, Q. Yang, W. Sun, S. C. Woods, D. D'Alessio, and P. Tso Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1130 - G1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. McClean, N. Irwin, R. S. Cassidy, J. J. Holst, V. A. Gault, and P. R. Flatt GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1746 - E1755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Basu, N. Charkoudian, W. Schrage, R. A. Rizza, R. Basu, and M. J. Joyner Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1289 - E1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Porksen, L. B. Nielsen, A. Kaas, M. Kocova, F. Chiarelli, C. Orskov, J. J. Holst, K. B. Ploug, P. Hougaard, L. Hansen, et al. Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2910 - 2916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Knop, T. Vilsboll, P. V. Hojberg, S. Larsen, S. Madsbad, A. Volund, J. J. Holst, and T. Krarup Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? Diabetes, August 1, 2007; 56(8): 1951 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Knop, T. Vilsboll, S. Larsen, P. V. Hojberg, A. Volund, S. Madsbad, J. J. Holst, and T. Krarup Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E324 - E330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D Green, P. R Flatt, and C. J Bailey Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 159 - 165. [Abstract] [PDF]
|
|
|
|
|
|
Y. Yamada, K. Miyawaki, K. Tsukiyama, N. Harada, C. Yamada, and Y. Seino Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide Diabetes, December 1, 2006; 55(Supplement_2): S86 - S91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ryskjaer, C. F Deacon, R. D Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsboll Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake Eur. J. Endocrinol., September 1, 2006; 155(3): 485 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Chaudhri, C. Small, and S. Bloom Gastrointestinal hormones regulating appetite Phil Trans R Soc B, July 29, 2006; 361(1471): 1187 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsukiyama, Y. Yamada, C. Yamada, N. Harada, Y. Kawasaki, M. Ogura, K. Bessho, M. Li, N. Amizuka, M. Sato, et al. Gastric Inhibitory Polypeptide as an Endogenous Factor Promoting New Bone Formation after Food Ingestion Mol. Endocrinol., July 1, 2006; 20(7): 1644 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Gunnarsson, M. S. Winzell, C. F. Deacon, M. O. Larsen, K. Jelic, R. D. Carr, and B. Ahren Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice Endocrinology, July 1, 2006; 147(7): 3173 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Meier, A. Gethmann, M. A. Nauck, O. Gotze, F. Schmitz, C. F. Deacon, B. Gallwitz, W. E. Schmidt, and J. J. Holst The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1118 - E1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Koehler and D. J. Drucker Activation of glucagon-like Peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes, May 1, 2006; 55(5): 1369 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B D Green, N Irwin, V A Gault, C J Bailey, F P M O'Harte, and P R Flatt Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice J. Endocrinol., May 1, 2005; 185(2): 307 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dungan and J. B. Buse Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide Clin. Diabetes, April 1, 2005; 23(2): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Druce, C. J. Small, and S. R. Bloom Minireview: Gut Peptides Regulating Satiety Endocrinology, June 1, 2004; 145(6): 2660 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Steil, C.-m. Hwu, R. Janowski, F. Hariri, S. Jinagouda, C. Darwin, S. Tadros, K. Rebrin, and M. F. Saad Evaluation of Insulin Sensitivity and {beta}-Cell Function Indexes Obtained From Minimal Model Analysis of a Meal Tolerance Test Diabetes, May 1, 2004; 53(5): 1201 - 1207. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
